Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
C
Chi Sheng Pharma & Biotech Co Ltd
TPEX:4111
Chi Sheng Pharma & Biotech Co Ltd
TPEX:4111
Price:
28.75
TWD
-0.86%
Market Closed
Market Cap:
NT$1.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Chi Sheng Pharma & Biotech Co Ltd
TPEX:4111
|
TW |
|
C
|
Comprehensive Healthcare Systems Inc
OTC:CMHSF
|
CA |
|
D
|
Diagnos Inc
OTC:DGNOF
|
CA |
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Chi Sheng Pharma & Biotech Co Ltd's stock price target?
Not Available
Chi Sheng Pharma & Biotech Co Ltd does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Chi Sheng Pharma & Biotech Co Ltd?
Projected CAGR
5%
5%
Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next -6 years is 5%.
What is the Gross Profit forecast for Chi Sheng Pharma & Biotech Co Ltd?
Projected CAGR
8%
8%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next -6 years is 8%.
What is the Operating Income forecast for Chi Sheng Pharma & Biotech Co Ltd?
Projected CAGR
18%
18%
Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next -6 years is 18%.
What is the Pre-Tax Income forecast for Chi Sheng Pharma & Biotech Co Ltd?
Projected CAGR
16%
16%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next -6 years is 16%.
What is the Net Income forecast for Chi Sheng Pharma & Biotech Co Ltd?
Projected CAGR
17%
17%
Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next -6 years is 17%.